Observational analysis reveals early-phase amyloid PET correlates with neurodegeneration markers, suggesting clinical value in Alzheimer's assessment.
Alzheimer's disease is marked by accumulation of amyloid-β (Aβ) and abnormal tau, associated with subsequent neurodegeneration. Validated markers of neurodegeneration include brain glucose metabolism, perfusion and atrophy. Dual-phase amyloid PET imaging allows to assess both Aβ buildup and perfusion changes through a single tracer injection. Increasing evidence supports the comparability of early-phase amyloid PET scans and glucose metabolism changes assessed by 18F-FDG PET at group and individual levels, regardless of the amyloid tracers and the disease, emphasizing the added value of dual-phase amyloid PET imaging protocols for clinical and research settings.
No takes yet. Share an insight, caveat, or question.
Boccalini et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: